BioWorld Asia

April 17, 2002

Medivir, Roche In $42M Pact For Preclinical HIV Compound

Swedish biotechnology firm Medivir AB unveiled Monday its biggest drug development deal to date a licensing agreement worth up to US$42 million with F. Hoffmann-La Roche Ltd. for Medivir’s candidate HIV treatment, MV026048. (BioWorld International) Read More

Abbott Seeks Approvals For CAT’s Monoclonal Antibody

Gene Expression Variations May Account For Chimp-Human Divide

Hybrigenics Raises $14.8M In Third Funding Round

Micromet, Enzon Collaborate On Single-Chain Antibodies

Other News To Note

Paradigm, Genmab Collaborate In Therapeutic Antibodies Deal

Start-Up CareX Raises $5.2M In Initial Funding Round

Epidauros, Pharmacia Broaden Pharmacogenetics Collaboration

Two Peptech Directors, Chairman Resign After Only Three Months

Prana Releases Positive News In Phase II of Alzheimer’s Drug

EU Advisory Group Calls For Changes In Biotech Proposals

Pharmexa Reveals GSK Option On Breast Cancer Vaccine

Today's news in brief

BioWorld

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...